De Novo Urologic Malignancies in Renal Transplant Recipients

Antunes, Hugo; Tavares-da-Silva, Edgar; Oliveira, Rui Caetano; Carvalho, Joana; Parada, B.; Bastos, C.; Figueiredo, Arnaldo

doi:10.1016/j.transproceed.2018.02.086

Cited by 17 publications

(26 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, the survival after diagnosis of RCC seems to be similar after KT (80% after five years; Table 3) compared to the data of the national registry (77%) [24]. This is in line with data after KT from the Frankfurt Transplant Center (83.5%) and Portugal (91.3%) [29,38]. The good outcome of RCC after KT might be caused by early detection of smaller cancer sizes, asymptomatic malignancies, lowstage and low-grade tumours due to the intensive monitoring of patients with end stage renal diseases posttransplant [20,23].…”

Section: Specific Cancers and Their Epidemiological Analysessupporting

confidence: 79%

“…PSA, digital rectal examination) was performed or not. Independent of the incidence, PC related death is rare [32,38]. No one died as a direct consequence of PC in the present investigation and survival was similar to matched controls (Fig 5 -panel c).…”

Section: Specific Cancers and Their Epidemiological Analysessupporting

confidence: 64%

“…Malignancies of the urinary system are increased after KT, but the increase of tumours of the prostate gland (PC; n = 15) was less pronounced in the present investigation as described earlier [20,29,33,38]. Two cancers of the bladder (ICD-10: C67; n = 6) were seen in females while all other malignancies of the urinary system were seen in man (Table 2).…”

Section: Specific Cancers and Their Epidemiological Analysessupporting

confidence: 58%

“…The malignant transformation of kidney cysts was assumed as one possible explanation [20,37]. According to the literature mortality of RCC was low in the present investigation, even the lowest among all investigated malignancies (Table 2) [2,38]. Interestingly, the survival after diagnosis of RCC seems to be similar after KT (80% after five years; Table 3) compared to the data of the national registry (77%) [24].…”

Section: Specific Cancers and Their Epidemiological Analysessupporting

confidence: 56%

See 3 more Smart Citations

De-novo malignancies after kidney transplantation: A long-term observational study

et al. 2020

View full text Add to dashboard Cite

Background De-novo malignancies after kidney transplantation represent one major cause for mortality after transplantation. However, most of the studies are limited due to small sample size, short follow-up or lack of information about cancer specific mortality. Methods This long-term retrospective analysis included all adult patients with complete follow-up that underwent kidney transplantation between 1995 and 2016 at our centre. All patients with diagnosis of malignancy excluding non-melanoma skin cancer (NMSC) were identified and a matched control group was assigned to the kidney transplant recipients with post-transplant malignancies. Results 1417 patients matched the inclusion criteria. 179 malignancies posttransplant were diagnosed in 154 patients (n = 21 with two, n = 2 patients with three different malignancies). Mean age at cancer diagnosis was 60.3±13.3 years. Overall incidence of de-novo malignancies except NMSC was 1% per year posttransplant. Renal cell carcinoma was the most common entity (n = 49, incidence 4.20 per 1000 patient years; cancer specific mortality 12%), followed by cancer of the gastro-intestinal tract (n = 30, 2.57; 50%), urinary system (n = 24, 2.06; 13%), respiratory system (n = 18, 1.54; 89%), female reproductive system (n = 15, 1.29; 13%), posttransplant lymphoproliferative disorders and haematological tumours (n = 14, 1.20; 21%), cancers of unknown primary (n = 7, 0.60 100%) and others (n = 22, 1.89; 27%). Male sex, re-transplantation and time on dialysis were associated with de-novo malignancies after transplantation. Conclusion De-novo malignancies continue to be a serious problem after kidney transplantation. To improve long-term outcome after Kidney transplantation, prevention and cancer screening should be more tailored and intensified.

show abstract

Section: Specific Cancers and Their Epidemiological Analysessupporting

confidence: 79%

Section: Specific Cancers and Their Epidemiological Analysessupporting

confidence: 64%

Section: Specific Cancers and Their Epidemiological Analysessupporting

confidence: 58%

Section: Specific Cancers and Their Epidemiological Analysessupporting

confidence: 56%

See 2 more Smart Citations

De-novo malignancies after kidney transplantation: A long-term observational study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…After solid organ transplantation, 74 patients developed de novo bladder cancer. 7 Antunes et al 8 reported that 61 de novo urologic malignancies have been recorded after renal transplantation. In these three reports, all de novo cancer patients were treated with posttransplantation immunosuppressants.…”

Section: Discussionmentioning

confidence: 99%

De <i>Novo</i> Papillary Urothelial Carcinoma at a Previous Ureteroneocystostomy Site for Benign Ureteral Injury

Park

2020

Korean J Urol Oncol

View full text Add to dashboard Cite

Ureteroneocystostomy is a good treatment option for iatrogenic ureteral injury. Common complications at ureteroneocystostomy sites are strictures, stone formation, urinary infections, fistulas, and ureteral leaks. Here, we report a rare occurrence of urothelial carcinoma occurring at the site of a previous ureteral reimplantation. A 57-year-old female presented in the Emergency Department with left flank pain and chills. She had undergone a left ureteroneocystostomy with Boari flap due to iatrogenic ureteral obstruction during a laparoscopic left ovarian cystic mass excision 2 years ago. Computed tomography revealed left ureteral obstruction by the tumor at the neo-ureterovesical junction site. Both anterograde and retrograde ureteral catheterization approaches failed. We conducted a left percutaneous nephrostomy and administered antibiotics. Urine cytology was negative. We performed a left ureterovesical obstructive mass excision and Yang-Monti ileal ureter reconstruction. Biopsy of the ureteral-obstructing tumor revealed a low-grade papillary urothelial carcinoma. The patient's symptoms and signs improved after surgery. To the best of our knowledge, this is the first report of a de novo urothelial carcinoma at the site of previous ureterovesical junction surgery. Urothelial carcinoma should be considered as one of the causes of stricture after ureteroneocystostomy.

show abstract

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney

et al. 2022

View full text Add to dashboard Cite

Introduction We present a case of urothelial carcinoma in a renal allograft successfully treated with pembrolizumab. Case presentation A 39‐year‐old woman presented with nausea and anorexia 9 years after a renal transplantation. Positron emission tomography revealed a neoplasm of the renal pelvis of the allograft and multiple lymph nodes with peritoneal metastasis. A diagnosis of a non‐muscle‐invasive bladder tumor with peritoneal dissemination and jejunal metastasis of urothelial carcinoma was made. After five cycles of gemcitabine and carboplatin, the tumor progressed and pembrolizumab was administered. One week after the first dose, the allograft was rejected, necessitating arterial embolization. After the second cycle, the patient developed Stevens‐Johnson syndrome. After discontinuing pembrolizumab, positron emission tomography revealed no increased tumor activity. A complete response was achieved for 21 months without additional treatment. Conclusion Pembrolizumab was effective in treating urothelial carcinoma of the renal allograft; however, allograft rejection and loss should be considered.

show abstract

De Novo Urologic Malignancies in Renal Transplant Recipients

Cited by 17 publications

References 30 publications

De-novo malignancies after kidney transplantation: A long-term observational study

De-novo malignancies after kidney transplantation: A long-term observational study

De <i>Novo</i> Papillary Urothelial Carcinoma at a Previous Ureteroneocystostomy Site for Benign Ureteral Injury

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney

Contact Info

Product

Resources

About